Download the app
App StorePlay Store
Beige
Login
← All tags

pharmaceuticals

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s launches generic Semaglutide in Canada first G7 approval could widen GLP-1 access fast

Dr Reddy’s Laboratories has launched a generic Semaglutide injection in Canada for adults with type 2 diabetes, following Health Canada approval granted on April 28, 2026. The move makes Canada the first G7 nation to authorize Semaglutide, positioning the company among the earliest generics entrants in that market. The launch follows Dr Reddy’s recent introduction in India under the brand name Obeda. Supplied as a sterile prefilled pen, it is offered in 2 mg and 4 mg strengths.

Summarised by Beize from a story on The Economic Times on 16 May 2026
Roche Pharma brings a seven minute under the skin immunotherapy for lung cancer in India

Roche Pharma brings a seven minute under the skin immunotherapy for lung cancer in India

Roche Pharma has launched Tecentriq, India’s first under-the-skin immunotherapy for non small cell lung cancer. The injection takes about seven minutes, aiming to cut the burden of longer intravenous sessions. By simplifying administration, the company says the treatment can improve patient experience and quality of life while delivering essential cancer care more conveniently.

Summarised by Beize from a story on The Economic Times on 14 May 2026

Your news, in seconds

App StorePlay Store
Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s Laboratories expects a gradual recovery in the coming fiscal year after last year’s profit dip hit by pressures in the US business. Growth remains solid across India, Europe, and emerging markets. The company’s outlook leans on upcoming launches including semaglutide and abatacept, alongside improved product mix and tighter cost controls to lift margins by FY27.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Pharma and NBFCs surge as mutual funds pivot to defensive bets in April

Pharma and NBFCs surge as mutual funds pivot to defensive bets in April

In April, Indian fund managers leaned into defensive stocks, with pharmaceuticals drawing fresh inflows tied to potential upside from the semaglutide patent expiry. Mutual funds also increased focus on NBFCs and asset management companies, adding PNB Housing Finance as money tilted toward retail lending. The broader shift points to worries over oil prices and West Asian geopolitical risks.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Pfizer eyes India growth wave with faster affordable launches in cancer obesity and vaccines

Pfizer eyes India growth wave with faster affordable launches in cancer obesity and vaccines

Pfizer is doubling down on India as its next growth engine, aiming to bring new medicines to market faster and at more affordable prices. The company sees major opportunity across cancer, obesity and vaccines, backed by plans for local clinical studies to support future launches and tailor outcomes for Indian patients.

Summarised by Beize from a story on The Economic Times on 13 May 2026
Zydus Lifesciences nears US oncology acquisition for up to 150 million to expand cancer distribution

Zydus Lifesciences nears US oncology acquisition for up to 150 million to expand cancer distribution

Zydus Lifesciences is reportedly close to buying a US oncology drug maker in a deal valued at $100 to $150 million. The acquisition is expected to help the Indian company build its own distribution network for anti-cancer drugs in the US, while also bringing along the target’s biologic drug pipeline. A deal is expected soon.

Summarised by Beize from a story on The Economic Times on 13 May 2026

Never miss a story

App StorePlay Store
Novartis ramps up India role driving early drug research for global innovation pipeline

Novartis ramps up India role driving early drug research for global innovation pipeline

Novartis says it is expanding how India contributes to its global drug development. The company is shifting more early stage research to India while doubling down on innovative medicines. With plans to bring additional new medicines to market soon, the move signals deeper long term commitment to India’s healthcare ecosystem and its workforce.

Summarised by Beize from a story on The Economic Times on 11 May 2026
Sun Pharma wins trademark battle as Bombay High Court blocks rival United Biotech

Sun Pharma wins trademark battle as Bombay High Court blocks rival United Biotech

The Bombay High Court ruled in favour of Sun Pharmaceutical Industries in a trademark dispute against United Biotech. It restrained United Biotech from using a similar mark, holding that Sun Pharma’s “Octride” has the stronger claim. The case relates to drugs used for acromegaly and carcinoid tumours, with the judgment protecting Sun’s reputation and goodwill.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Emcure ramps up R and D and bets on global acquisitions for next wave of growth

Emcure ramps up R and D and bets on global acquisitions for next wave of growth

Emcure Pharmaceuticals is accelerating domestic expansion while scaling R&D and manufacturing capacity. The company is also scouting acquisition opportunities both in India and abroad, aiming to add new products to fuel growth. A key driver is its partnership with Novo Nordisk for GLP-1 therapies, alongside a pipeline of complex injectables poised to support momentum ahead.

Summarised by Beize from a story on The Economic Times on 6 May 2026
Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval

Sun Pharmaceutical Industries is exploring multiple financing routes for its proposed $12 billion acquisition of Organon & Co. Reports say lenders are considering swapping Organon bondholders into Sun Pharma debt, including a possible euro-denominated bond, while Sun Pharma also plans to raise $3 billion to $4 billion in offshore loans. Deal approvals are expected by December.

Summarised by Beize from a story on The Economic Times on 6 May 2026

Reading on mobile?

App StorePlay Store
India ramps up drug regulator overhaul with recruitment of 1500 scientists and tech specialists

India ramps up drug regulator overhaul with recruitment of 1500 scientists and tech specialists

India’s drug regulator is starting a major overhaul by planning to recruit more than 1,500 scientists and technology specialists. The move is designed to streamline drug approval processes and bring them closer to international benchmarks. Officials say the expanded expertise will strengthen pharmaceutical governance and help the regulator work faster and more consistently as the sector evolves.

Summarised by Beize from a story on The Economic Times on 5 May 2026
CDSCO to reject drug applications with unanswered queries within 30 days from May 4

CDSCO to reject drug applications with unanswered queries within 30 days from May 4

The Central Drugs Standard Control Organisation has warned that drug applications with unanswered queries will be rejected if applicants do not respond within 30 days. In a public notice dated May 4, CDSCO said several applications have remained pending at the applicant’s end since 2016, signalling stricter timelines for regulatory processing.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Pfizer rallies after strong quarter and legal wins that could extend key drug profits beyond 2028

Pfizer rallies after strong quarter and legal wins that could extend key drug profits beyond 2028

Pfizer reported higher-than-expected first-quarter sales and profit, boosting investor confidence. The company also pointed to a patent extension for its Vyndamax heart treatment and a favorable European court ruling tied to its COVID-19 vaccine. Together, the wins are expected to help secure stronger growth prospects after 2028.

Summarised by Beize from a story on The Economic Times on 5 May 2026
US warns India over IP duties and AI blanket licensing in new working paper

US warns India over IP duties and AI blanket licensing in new working paper

The US has raised fresh concerns about India’s high customs duties on IP-intensive goods and a proposed mandatory blanket license for AI developers using copyrighted works. India is still on the US “Priority Watch List” over weak IP protection, with fears including trade secret disclosure and patent revocations, especially affecting the pharmaceutical sector.

Summarised by Beize from a story on The Economic Times on 4 May 2026

Follow your favourite sources

App StorePlay Store
Aurobindo Pharma arm CuraTeQ clears Health Canada hurdle for biosimilar Bevqolva

Aurobindo Pharma arm CuraTeQ clears Health Canada hurdle for biosimilar Bevqolva

Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its cancer biosimilar Bevqolva, a bevacizumab-based treatment used across multiple cancers. The development signals Health Canada’s confirmation of safety and efficacy, paving the way for broader access to potential cost-effective options for patients in Canada.

Summarised by Beize from a story on The Economic Times on 1 May 2026
ORS sales slump as tighter labelling rules hit sugary drink claims

ORS sales slump as tighter labelling rules hit sugary drink claims

India’s ORS market has taken a hit after the government tightened labelling norms, limiting when sugary drinks can be marketed as ORS. The change has disrupted supply and seasonal purchasing patterns, pressuring pharmaceutical firms that rely on predictable demand spikes. Companies now face a tougher path to maintain sales as compliance reduces the category’s appeal.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
RPG Life Sciences to scale API business and target GLP 1 entry by August September

RPG Life Sciences to scale API business and target GLP 1 entry by August September

RPG Life Sciences says it is doubling down on its API business as the growth engine, while lining up a significant acquisition to expand capacity. The company also plans to enter the GLP-1 weight-loss therapy market by August-September, despite geopolitical risks. Its strategy centers on niche, complex molecules and moving into new therapy areas.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026
Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results

Eli Lilly raised its annual profit and revenue outlook after a stronger-than-expected first quarter, powered by steady demand for its GLP-1 therapies. Results followed the company’s initial reporting since launching its oral GLP-1 pill, Foundayo, with continued momentum for weight-loss and diabetes brands Zepbound and Mounjaro.

Summarised by Beize from a story on The Economic Times on 30 Apr 2026

Stay informed on the go

App StorePlay Store
Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma buys Organon for 11 75 billion boosting scale but integration debt could bite

Sun Pharma’s $11.75 billion acquisition of Organon & Co is set to expand its global footprint, commercial reach, and product diversification, including women’s health and biosimilars. The move aims to strengthen long-term growth, but success will hinge on how smoothly management integrates Organon’s operations and controls the deal’s debt burden.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma buys Organon to boost oncology dermatology and women health fast

Sun Pharma is strengthening its global footprint with the acquisition of New Jersey based Organon. The deal expands its portfolio across dermatology, oncology, and women’s health while creating a route into markets such as China and Brazil. With strong finances underpinning the move, Sun expects quicker returns as it scales the combined capabilities and reach.

Summarised by Beize from a story on The Economic Times on 27 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play